NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Jazz Pharmaceuticals PLC JAZZ
17 fiscal years on record · USD · FY2025 reported · SEC filings only
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
USD 4.3B
Revenue, FY2025 · full 17-year series below
Revenue $B
Net income $B
FY2025 · Revenue 4.3 · Net income -0.4
2B3B
2009201220152018202120242025
Compound annual growth
Revenue compounded at +12.5% a year over the five years to FY2025.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−8 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -10.1% · Net -8.3%
20%40%-5%-10%
200920172025
ROE
FY2025 · ROE -8.5%
50%100%
200920172025
Three returns, three denominators.
Each USD of equity lost 8 cents this year.
The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 4.3 | 4.1 | 3.8 | 3.7 | 3.1 | 2.4 | 2.2 | 1.9 | 1.6 | 1.5 | 1.3 | 1.2 | 0.9 | 0.6 | 0.3 | 0.2 | 0.1 |
| Operating income $B | −0.4 | 0.7 | 0.6 | −0.1 | 0.2 | 0.4 | 0.5 | 0.6 | 0.5 | 0.6 | 0.5 | 0.2 | 0.3 | 0.2 | 0.1 | 0.1 | 0.0 |
| EBITDA $B | −0.4 | 0.7 | 0.6 | −0.0 | 0.2 | 0.4 | 0.5 | 0.6 | 0.5 | 0.6 | 0.5 | 0.2 | 0.3 | 0.2 | 0.1 | 0.1 | 0.0 |
| Income tax $B | −0.3 | −0.1 | −0.1 | −0.2 | 0.2 | 0.0 | −0.1 | 0.1 | −0.0 | 0.1 | 0.1 | 0.1 | 0.1 | −0.1 | 0.0 | 0.0 | ◌ |
| Net income $B | −0.4 | 0.6 | 0.4 | −0.2 | −0.3 | 0.2 | 0.5 | 0.4 | 0.5 | 0.4 | 0.3 | 0.1 | 0.2 | 0.3 | 0.1 | 0.0 | −0.0 |
| Free cash flow $B | 1.3 | 1.4 | 1.1 | 1.2 | 0.8 | 0.9 | 0.7 | 0.8 | 0.7 | 0.6 | 0.5 | 0.4 | 0.3 | 0.2 | 0.2 | 0.1 | −0.0 |
| EPS, diluted $ | −5.84 | 8.65 | 6.10 | −3.58 | −5.52 | 4.22 | 9.09 | 7.30 | 7.96 | 6.41 | 5.23 | 0.93 | 3.51 | 4.79 | 2.67 | 0.83 | −0.23 |
| Dividend / sh $ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ROE % | −8.5 | 14.3 | 12.2 | −6.4 | −8.6 | 7.0 | 17.8 | 16.3 | 21.3 | 22.8 | 22.2 | 4.4 | 17.9 | 43.9 | 111.9 | — | — |
| Shares out B | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.04 | 0.04 | ◌ |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Provenance
Company facts, as filed
How we verify · 0 failures in 66 reconciliationsAUDITED
Reconciled in 17 of the 17 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Two checks were skipped: EPS is not tagged before 2009.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code L2
Fiscal year endsDecember 31
Data on record since2009